These results indicated that the titer of the autoantibodies against NPM1 in HCC sera increased at 3–6 months before the diagnosis of HCC, and the autoantibodies against NPM1 in HCC sera may be potential biomarkers for early-stage HCC screening and diagnosis. The gene discussed is NPM1; the disease is hepatocellular carcinoma.